TickerFacts.

Calidi Biotherapeutics, Inc. (CLDI): Shareholders' Equity

Annual figures by period end, from SEC filings.

$3.76M
As of 2025-12-31
$3.13M
As of 2026-06-30
2021-12-31: -$14.69M2022-12-31: -$50.44M2023-12-31: -$8.23M2024-12-31: $1.53M2025-12-31: $3.76M$3.76M
2021-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$3.76M+145.0%2026-03-27, Balance as of period end
2024-12-31$1.53Mn/m2026-03-27, Balance as of period end
2023-12-31-$8.23Mn/m2025-03-31, Balance as of period end
2022-12-31-$50.44Mn/m2024-03-15, Balance as of period end
2021-12-31-$14.69Mn/a2023-03-31, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Calidi Biotherapeutics, Inc. (CLDI)2025-12-31$3.76M+145.0%
Greenland Mines Ltd (GRML)2025-12-31$9.46M+698.4%
Dyadic International Inc (DYAI)2025-12-31$1.23M-50.1%
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31$7.51M+18.5%
VivoSim Labs, Inc. (VIVS)2026-03-31-$1.10Mn/m
Silexion Therapeutics Corp (SLXN)2025-12-31$2.60Mn/m
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$8.10M-18.8%
Exozymes Inc. (EXOZ)2025-12-31$3.40M-67.4%
AIM ImmunoTech Inc. (AIM)2025-12-31-$9.78Mn/m

Compare CLDI, GRML, DYAI, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗